Abstract
Prevalence and impact of occult HBV infection in HIV positive patients is controversial. The aims of this study were to determine the prevalence of occult HBV infection and its impact on histological and virological parameters. 52 HIV/HCV (but HBsAg-negative) co-infected patients, 29 HBsAg and anti-HCV negative chronic hepatitis, and 20 HBsAg positive chronic hepatitis controls were studied. DNA was extracted from frozen biopsies and amplified with primers for S, C and X regions, and for (ccc) HBV-DNA. Sera were tested for HBV-DNA with two quantitative assays (Cobas Amplicor HBV Monitor, and the real-time COBAS (r) Taqman HBV Test, Roche Diagnostics, UK). Occult HBV infection was detected in 7 (13.4%) liver biopsies of the study group, and in none case of the non viral chronic hepatitis group (p=0.04). All serum samples were HBV-DNA negative with Cobas Amplicor HBV monitor assay, while 3 cases were found positive with real time PCR. Statistical analysis didnt show any impact of occult HBV infection on liver histology, CD4+ cells count, HIV and HCV load, and ALT levels. Occult B infection is relatively frequent in HIV/HCV co-infected patients, and is underestimated by common HBV-DNA serological assays. However, it doesnt seem to exert a relevant impact.
Keywords: Occult HBV, HIV/HCV-co-infection, chronic hepatitis, HBV-DNA
Current HIV Research
Title: Impact of Occult HBV Infection in HIV/HCV Co-Infected Patients: HBVDNA Detection in Liver Specimens and in Serum Samples
Volume: 6 Issue: 2
Author(s): Paolo Fabris, Maria R. Biasin, Maria T. Giordani, Laura Berardo, Vania Menini, Antonio Carlotto, Maria G. Miotti, Vinicio Manfrin, Vincenzo Baldo, Gaia Nebbia and Domenico Infantolino
Affiliation:
Keywords: Occult HBV, HIV/HCV-co-infection, chronic hepatitis, HBV-DNA
Abstract: Prevalence and impact of occult HBV infection in HIV positive patients is controversial. The aims of this study were to determine the prevalence of occult HBV infection and its impact on histological and virological parameters. 52 HIV/HCV (but HBsAg-negative) co-infected patients, 29 HBsAg and anti-HCV negative chronic hepatitis, and 20 HBsAg positive chronic hepatitis controls were studied. DNA was extracted from frozen biopsies and amplified with primers for S, C and X regions, and for (ccc) HBV-DNA. Sera were tested for HBV-DNA with two quantitative assays (Cobas Amplicor HBV Monitor, and the real-time COBAS (r) Taqman HBV Test, Roche Diagnostics, UK). Occult HBV infection was detected in 7 (13.4%) liver biopsies of the study group, and in none case of the non viral chronic hepatitis group (p=0.04). All serum samples were HBV-DNA negative with Cobas Amplicor HBV monitor assay, while 3 cases were found positive with real time PCR. Statistical analysis didnt show any impact of occult HBV infection on liver histology, CD4+ cells count, HIV and HCV load, and ALT levels. Occult B infection is relatively frequent in HIV/HCV co-infected patients, and is underestimated by common HBV-DNA serological assays. However, it doesnt seem to exert a relevant impact.
Export Options
About this article
Cite this article as:
Fabris Paolo, Biasin R. Maria, Giordani T. Maria, Berardo Laura, Menini Vania, Carlotto Antonio, Miotti G. Maria, Manfrin Vinicio, Baldo Vincenzo, Nebbia Gaia and Infantolino Domenico, Impact of Occult HBV Infection in HIV/HCV Co-Infected Patients: HBVDNA Detection in Liver Specimens and in Serum Samples, Current HIV Research 2008; 6 (2) . https://dx.doi.org/10.2174/157016208783885029
DOI https://dx.doi.org/10.2174/157016208783885029 |
Print ISSN 1570-162X |
Publisher Name Bentham Science Publisher |
Online ISSN 1873-4251 |
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
Related Articles
-
Alternatives to Conventional Vaccines - Mediators of Innate Immunity
Current Drug Targets Role of mTOR in Hematological Malignancies
Current Cancer Therapy Reviews Liver Stem Cells and Possible Clinical Applications
Current Stem Cell Research & Therapy Brutons Tyrosine Kinase as a New Therapeutic Target
Anti-Cancer Agents in Medicinal Chemistry Anticancer Metallotherapeutics in Preclinical Development
Current Medicinal Chemistry Exosomes and the Emerging Field of Exosome-Based Gene Therapy
Current Gene Therapy Dual-Specificity MAP Kinase Phosphatases as Targets of Cancer Treatment
Anti-Cancer Agents in Medicinal Chemistry Reposition of the Fungicide Ciclopirox for Cancer Treatment
Recent Patents on Anti-Cancer Drug Discovery Phosphodiesterase Inhibition as a Therapeutic Target for Brain Ischemia
CNS & Neurological Disorders - Drug Targets Fragment-Based Optimization of Small Molecule CXCL12 Inhibitors for Antagonizing the CXCL12/CXCR4 Interaction
Current Topics in Medicinal Chemistry The Proteins Interacting with Prmt5 in Medaka (Oryzias latipes) Identified by Yeast Two-Hybridization
Protein & Peptide Letters Editorial (Thematic Issue: Advances in Drug Discovery for the Treatment of Cancer: Many Approaches, One Goal)
Current Topics in Medicinal Chemistry Monofunctional Platinum (PtII) Compounds – Shifting the Paradigm in Designing New Pt-based Anticancer Agents
Current Medicinal Chemistry Erdafitinib as a Novel and Advanced Treatment Strategy of Metastatic Urothelial Carcinoma
Anti-Cancer Agents in Medicinal Chemistry Ring-Expanded (“Fat”) Nucleosides as Broad-Spectrum Anticancer and Antiviral Agents
Current Topics in Medicinal Chemistry Histone Modifications as Molecular Targets in Nasopharyngeal Cancer
Current Medicinal Chemistry Ras-Induced Senescence and its Physiological Relevance in Cancer
Current Cancer Drug Targets The N-Terminal Region of HIV-1 Tat Protein Binds CD127 in Human CD8 T Cells to Target the Receptor for Down Regulation Through Tat's Basic Region
Current HIV Research The Use of PET for Radiotherapy
Current Medical Imaging Angiogenesis Inhibitors: Perspectives for Medical, Surgical and Radiation Oncology
Current Pharmaceutical Design